ONESOURCE· Health Care› Biotechnology

Onesource Specialty Pharma Ltd

Stage 4 · Declining · week 3

As of 16 Oct 2026, Onesource Specialty Pharma is in Stage 4 — declining, a downtrend, in week 3 (since 29 Sep 2026). It closed at ₹1,408, 25.5% below its 52-week high and below its 200-day average, which is falling. In Health Care, 40.0% of stocks are in Stage 2.

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in I… More about the company

₹1,407.8
-1.77% today
₹16,144 Cr · Mid cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dBiotechnology 22.2%-11.1 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ONESOURCE early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-25.5%
₹1,114 lo₹1,889.8 hi
25.5% below 52W high — ongoing decline
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 3
1w13w26w
Week 3 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-10.3%
200 DMA: ₹1,569.6 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.40x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -3.1% vs MA50 -3.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-11.8%
3M
-14.8%
6M
-6.5%
YTD
-17.4%
1Y
-24.4%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 66 Stage 2 leaders. See Health Care Stage 2 →
Industry
Biotechnology
↓ Peaking
Stage 2%
22.2%
20d Δ
-11.1pp
1M return
-7.7%
3M return
-6.9%
Industry Stage-2 % · last 20 days
Industry has 2 Stage 2 leaders. See Biotechnology Stage 2 →
Stage Cycle Timeline2025-01-24 → 2026-10-16
S? 42w
S4 19w
S3 10w
2025-01-242026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S3 4w → S4 19w → S1 6w → S2 7w → S3 10w → S4 3w current
Total tracked: 90 weeks across 7 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-06-05
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S4
Wk 3 · Vol 0.40x
2026-10-15S4
Wk 3 · Vol 0.32x
2026-10-14S4
Wk 3 · Vol 1.14x
2026-10-13S4
Wk 2 · Vol 0.85x
2026-10-12S4
Wk 2 · Vol 0.62x
2026-10-09S4
Wk 2 · Vol 0.72x
2026-10-08S4
Wk 2 · Vol 0.85x
2026-10-07S4
Wk 2 · Vol 0.36x
2026-10-06S4
Wk 1 · Vol 0.52x
2026-10-05S4
Wk 1 · Vol 0.53x
2026-10-01S4
Wk 1 · Vol 2.18x
2026-09-30S4
Wk 1 · Vol 0.70x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹1,539.7
200 DMA
₹1,569.6
52W High
₹1,889.8
52W Low
₹1,114
5D Low
₹1,407.8
Resistance levels (recent highs)
20d High
₹1,602.6
60d High
₹1,749.7
120d High
₹1,867.4
250d High
₹1,877.8
Next resistance
+13.8%
to 20d High
Ask the Market AI about ONESOURCEAsk →
About this companyHealth Care· Biotechnology

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.